Ultra-processed food consumption and non-alcoholic fatty liver disease, metabolic syndrome and insulin resistance: A systematic review

Grinshpan, Laura Sol; Eilat-Adar, Sigal; Ivancovsky-Wajcman, Dana; Kariv, Revital; Gillon-Keren, Michal; Zelber-Sagi, Shira

doi:10.1016/j.jhepr.2023.100964

Cited by 5 publications

(1 citation statement)

References 109 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is also more prevalent in individuals with cardiovascular/metabolic risk factors, including hypertension, DM2, abdominal obesity, dyslipidemia, and metabolic syndrome[ 26 , 27 ]. Its occurrence has also been positively associated with the consumption of ultra processed food, red meat, fast food, sugars and refined cereal, whereas the consumption of whole-wheat cereal, fiber and olive oil seems to have a protective effect[ 28 - 32 ]. The prevalence of MASLD ranges from 13.5% in Africa to 31.8% in the Middle East.…”

Section: Metabolism Dysfunction-associated Steatotic Liver Diseasementioning

confidence: 99%

Liver disease in patients with transfusion-dependent β-thalassemia: The emerging role of metabolism dysfunction-associated steatotic liver disease

Fragkou,

Vlachaki,

Goulis

et al. 2024

World J Hepatol

View full text Add to dashboard Cite

In this Editorial, we highlight the possible role that metabolism dysfunction-associated steatotic liver disease (MASLD) may play in the future, regarding liver disease in patients with transfusion-dependent β-thalassemia (TDBT). MASLD is characterized by excessive accumulation of fat in the liver (hepatic steatosis), in the presence of cardiometabolic factors. There is a strong correlation between the occurrence of MASLD and insulin resistance, while its increased prevalence parallels the global epidemic of diabetes mellitus (DM) and obesity. Patients with TDBT need regular transfusions for life to ensure their survival. Through these transfusions, a large amount of iron is accumulated, which causes saturation of transferrin and leads to the circulation of free iron molecules, which cause damage to vital organs (primarily the liver and myocardium). Over the past, the main mechanisms for the development of liver disease in these patients have been the toxic effect of iron on the liver and chronic hepatitis C, for which modern and effective treatments have been found, resulting in successful treatment. Additional advances in the treatment and monitoring of these patients have led to a reduction in deaths, and an increase in their life expectancy. This increased survival makes them vulnerable to the onset of diseases, which until recently were mainly related to the non-thalassemic general population, such as obesity and DM. There is insufficient data in the literature regarding the prevalence of MASLD in this population or on the risk factors for its occurrence. However, it was recently shown by a study of 45 heavily transfused patients with beta-thalassemia (Padeniya et al , BJH), that the presence of steatosis is a factor influencing the value of liver elastography and thus liver fibrosis. These findings suggest that future research in the field of liver disease in patients with TDBT should be focused on the occurrence, the risk factors, and the effect of MASLD on these patients.

show abstract